DPP-4 inhibitors have a potent hypoglycemic effect during the hyperglycemic state via glucose-dependent insulin secretion by increasing the active serum GLP-1 and GIP concentration, or by reducing hypoglycemia by diminishing insulin secretion and cancelling glucagon suppression under normal to hypoglycemic conditions [20]. Here, GCG is linked to Hypoglycemia.